Company intelligence / Profile preview
Beijing Asia-East Bio-Pharmaceutical
Beijing, Beijing Shi, Chinacncbl.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Beijing Asia-East Bio-Pharmaceutical has multiple commercialized drugs including herbal medicines for asthma, a recombinant hepatitis B vaccine produced in CHO cells, and a biosimilar insulin product. The company’s pipeline covers respiratory diseases, infectious diseases, nervous system diseases, immune system diseases, and endocrinology/metabolic disorders. All listed programs have reached approval status in China.
- Therapeutic areas
- PulmonologyInfectious DiseasesEndocrinology
- Modalities
- Herbal medicineProphylactic vaccineBiosimilarHormone
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on Beijing Asia-East Bio-Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Beijing Asia-East Bio-Pharmaceutical.